Published in J Immunol Res on January 16, 2014
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. J Exp Clin Cancer Res (2015) 0.99
Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer (2016) 0.90
Dendritic cell defects in the colorectal cancer. Hum Vaccin Immunother (2014) 0.82
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med (2014) 0.81
IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer. Cancer Microenviron (2015) 0.80
Gene expression and pathway analysis of human hepatocellular carcinoma cells treated with cadmium. Toxicol Appl Pharmacol (2015) 0.80
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. Gastroenterol Res Pract (2016) 0.79
Drug Trafficking into Macrophages via the Endocytotic Receptor CD163. Membranes (Basel) (2015) 0.78
Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling. Oncotarget (2017) 0.75
Alterative Expression and Localization of Profilin 1/VASPpS157 and Cofilin 1/VASPpS239 Regulates Metastatic Growth and Is Modified by DHA Supplementation. Mol Cancer Ther (2016) 0.75
FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer. Oncol Lett (2016) 0.75
Reciprocal influence of B cells and tumor macro and microenvironments in the Apc(Min/+) model of colorectal cancer. Oncoimmunology (2017) 0.75
Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response. Onco Targets Ther (2017) 0.75
Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Cancer-related inflammation. Nature (2008) 34.21
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 13.44
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol (2010) 5.10
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol (2012) 4.47
Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol (2012) 4.30
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 4.22
Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 4.02
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75
T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 3.40
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol (1997) 3.09
Cancer: Inflaming metastasis. Nature (2009) 3.09
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer (2006) 3.05
Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev (2008) 2.95
Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol (2011) 2.92
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85
Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood (2004) 2.80
Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 2.80
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res (2007) 2.63
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun (2007) 2.44
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol (2008) 2.26
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 2.07
The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One (2012) 2.05
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96
Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol (2004) 1.89
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 1.73
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res (2010) 1.72
The inflammatory microenvironment in colorectal neoplasia. PLoS One (2011) 1.62
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer (2005) 1.59
Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol (2005) 1.58
Evolving treatment of advanced colon cancer. Annu Rev Med (2009) 1.56
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol (2013) 1.49
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res (2008) 1.48
The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int J Dev Biol (2011) 1.43
Colon cancer: it's CIN or CIMP. Clin Cancer Res (2008) 1.41
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med (2010) 1.33
Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Aspects Med (2011) 1.27
The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol (2008) 1.25
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood (2012) 1.24
Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int (2012) 1.24
High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer (2008) 1.20
Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer (2009) 1.16
Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer (2010) 1.10
The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 1.06
Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology (2009) 1.05
The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep (2009) 1.04
On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol (2013) 1.01
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol (2012) 1.00
Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer (2012) 0.97
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol (2008) 0.96
The emerging "hallmarks" of metabolic reprogramming and immune evasion: distinct or linked? Cancer Res (2013) 0.89
The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology (2012) 0.89
Premetastatic niche: ready for new therapeutic interventions? Expert Opin Ther Targets (2012) 0.87
Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling. PLoS One (2013) 0.84
Molecular pathology of colorectal carcinoma. A systematic review centred on the new role of the pathologist. Pathologica (2012) 0.81
Right-sided rhabdoid colorectal tumors might be related to the serrated pathway. Diagn Pathol (2013) 0.80
Risk factors. CD8+:FOXP3+ cell ratio is a novel survival marker for colorectal cancer. Nat Rev Clin Oncol (2010) 0.78
Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract (2014) 0.96
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. Gastroenterol Res Pract (2016) 0.79
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol (2017) 0.75